{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/cardinal-health-cah/",
 "dataUrl": "https://clearank.com/stock/cardinal-health-cah/data.json",
 "title": "Cardinal Health (CAH) Stock Forecast & Price Target (2026)",
 "description": "Cardinal Health (CAH) stock forecast 2026: buy, hold or sell? Analysts see a median target of $290. Topped estimates in 7 of 7 reports.",
 "headline": "Cardinal Health, Inc. (CAH)",
 "published": "2026-11-09T18:46:30+00:00",
 "modified": "2026-11-09T18:46:30.404+00:00",
 "generated": "2026-11-11T13:24:46.947Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by Jacob Bakshi, Senior Market Strategist; prices delayed by up to a minute.",
 "asset": {
  "ticker": "CAH",
  "name": "Cardinal Health, Inc.",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Medical Distribution",
  "country": "United States",
  "website": "https://www.cardinalhealth.com"
 },
 "quote": {
  "price": 276.79,
  "previousClose": 274.29,
  "change": 2.5,
  "changePercent": 0.9114,
  "open": 274.34,
  "high": 278.065002,
  "low": 272.88,
  "volume": 1600964,
  "averageVolume": 1877486,
  "marketCap": 63976317048,
  "fiftyTwoWeekHigh": 286.29001,
  "fiftyTwoWeekLow": 180.45,
  "marketOpen": false,
  "asOf": "2026-11-10T23:51:57.000Z"
 },
 "statistics": {
  "pe": 35.49,
  "eps": 7.8,
  "dividendYield": 0.007420788055175836,
  "beta": 0.521,
  "priceToSales": 0.24596694,
  "priceToBook": -23.790000209724326,
  "revenueTtm": 257752006656,
  "grossMargin": 0.0402060560371906,
  "returnOnEquity": null
 },
 "technicals": {
  "rsi": 76.52,
  "macd": 8.62,
  "sma50": 242.12,
  "sma200": 224.1,
  "rsiSignal": "Overbought",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Buy",
  "score": 77,
  "consensus": "Buy",
  "fairValue": null,
  "analystTarget": 290,
  "analystCount": 17,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-11-10T23:51:57.000Z",
  "priceAtAnalysis": 276.79001,
  "volatility": {
   "daily": 1.58,
   "risk": "standard"
  }
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 207.16,
    "base": 301.9,
    "upside90th": 439.98
   },
   {
    "year": 2028,
    "downside10th": 193.31,
    "base": 329.29,
    "upside90th": 560.91
   },
   {
    "year": 2029,
    "downside10th": 187.06,
    "base": 359.17,
    "upside90th": 689.6
   },
   {
    "year": 2030,
    "downside10th": 184.45,
    "base": 391.75,
    "upside90th": 832.03
   }
  ]
 },
 "faqCount": 7,
 "atAGlance": {
  "asOf": "November 10, 2026",
  "rating": "Buy",
  "score": 77,
  "evidence": [
   {
    "label": "Trend",
    "text": "Up: the price is above both its 50- and 200-day moving averages ($242.12 and $224.10)."
   },
   {
    "label": "Earnings",
    "text": "CAH beat estimates in 7 of its last 7 quarters, yet fell in the first session after 3 of those beats."
   },
   {
    "label": "Insiders",
    "text": "Insiders sold $112.5M and made no open-market purchases over the last 18 months."
   },
   {
    "label": "Valuation",
    "text": "P/E of 35.5 against 31.9 for the Healthcare sector: broadly in line with peers (+11%)."
   }
  ]
 },
 "figures": {
  "asOf": "November 10, 2026",
  "earningsReaction": {
   "quarters": 7,
   "beats": 7,
   "fellFirstSessionAfterBeat": 3,
   "latestReport": "Nov 5, 2026",
   "latestSurprisePercent": 10.88,
   "latestFirstSessionMovePercent": 1.46
  },
  "insiders": {
   "windowMonths": 18,
   "soldValue": 112507335,
   "boughtValue": 0,
   "sales": 19,
   "purchases": 0,
   "note": "open-market transactions only; grants and option exercises excluded"
  },
  "drawdown": {
   "years": 10,
   "worstFallPercent": -45.85,
   "peak": "March 2017",
   "trough": "March 2020",
   "recoveredBy": "August 2022",
   "recoveryMonths": 29,
   "belowThatPeakNowPercent": null,
   "fromHighNowPercent": 0,
   "oneYearHoldsPositivePercent": 72,
   "dividendsReinvested": true
  },
  "seasonality": {
   "years": 10,
   "bestMonth": {
    "month": "Nov",
    "averagePercent": 8.82,
    "upYearsPercent": 78
   },
   "worstMonth": {
    "month": "Dec",
    "averagePercent": -3.09,
    "upYearsPercent": 22
   }
  },
  "correlations": null,
  "analystTargets": {
   "analysts": 17,
   "low": 260,
   "median": 290,
   "high": 330,
   "mean": 291.53,
   "buy": 14,
   "hold": 3,
   "sell": 0
  },
  "dividend": {
   "yieldPercent": 0.7421,
   "annualPerShare": 2.05
  },
  "simulation": {
   "year": 2030,
   "base": 391.75,
   "percentile10": 184.45,
   "percentile90": 832.03,
   "note": "Monte Carlo simulation outcomes, not price targets"
  }
 },
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "ch-overview",
   "title": "CAH stock today, November 11, 2026: price, news and analyst targets",
   "text": [
    "As of November 10, 2026, Cardinal Health, Inc. (CAH) trades at $276.79. Wall Street's median 12-month price target is $290.00 across 17 analysts, 4.8% above the price. CleaRank rates it Buy with a score of 77/100.",
    "Cardinal Health is trading near the top of its 52-week range after a run of analyst reaffirmations and a strong fiscal first-quarter report. The stock closed at $276.79 and sits 91% of the way up its 52-week range, with the 52-week high at $286.29. Shares are up 16.51% over the past month and 51.62% over six months, and the stock is above its 50-day and 200-day moving averages ($242.12 and $224.10). The question for investors is whether earnings growth can keep pace with a share price that already prices in much of the recovery. CleaRank rates the stock Buy with a score of 77 out of 100.",
    "Cardinal Health has beaten EPS estimates in all seven of the recent reports on the earnings record. The November 5, 2026 report delivered adjusted EPS of $3.26 against an estimate of $2.94, a beat of 10.88%, and the stock rose 1.46% in the first session afterward. The August 11, 2026 report beat by 7.44%, but the shares fell 2.54% in the next session. Across the seven reports, three beats were followed by a lower share price, so a beat has not reliably translated into a gain on the day.",
    "Margins are thin: the net profit margin is 0.70% and the operating margin is 1.34%. The company's health score on CleaRank is 3 out of 5, reflecting solid execution on earnings but a slower top line and narrow profitability.",
    "The trailing P/E of 35.49 sits 11.3% above the Healthcare sector median of 31.9, which is broadly in line with peers. The price-to-sales ratio of 0.25 is far below the sector median of 3.4, reflecting how low margins are relative to sales. Of 17 analysts, 14 rate the stock buy or strong buy, three hold it and none sell it. Morgan Stanley kept its Overweight rating on October 30, 2026, and RBC Capital and Evercore ISI both kept Outperform ratings on November 6, 2026.",
    "Insiders sold $112.5M of stock over the last 18 months across 19 sales and made no open-market purchases. Such sales are often planned in advance or made to cover tax on vesting shares, so they carry less weight than purchases would.",
    "CleaRank score 77/100 (Buy). 16 of 19 checks pass: trend 4 of 4, momentum 2 of 3, valuation and quality 4 of 5, analysts 2 of 3, track record 4 of 4.",
    "Cardinal Health, Inc. is a healthcare services and products company that supports the flow of medicines, medical supplies, and related solutions across the healthcare system. Cardinal Health distributes pharmaceuticals and specialty products, manufactures and distributes medical and laboratory products, and provides performance and data solutions for healthcare facilities. Its operations serve hospitals, health systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients at home."
   ]
  },
  {
   "id": "ch-news",
   "title": "CAH stock news",
   "text": [
    "November 6, 2026·RBC Capital",
    "RBC Capital and Evercore ISI both kept Outperform ratings on November 6, 2026, the first session after the earnings report. Reaffirmations after a beat support the analyst case for further upside.",
    "November 5, 2026·Earnings report",
    "Adjusted EPS of $3.26 beat the $2.94 estimate by 10.88%, and the shares rose 1.46% in the next session. This is the strongest recent evidence that earnings are running ahead of expectations.",
    "October 30, 2026·Morgan Stanley",
    "Morgan Stanley kept its Overweight rating on October 30, 2026, adding to a set of institutional endorsements in the weeks before the report.",
    "October 20, 2026·Mizuho",
    "Mizuho kept its Outperform rating on October 20, 2026, a reaffirmation that keeps the Street's positive stance in place ahead of the report.",
    "August 19, 2026·RBC Capital",
    "RBC Capital started coverage at Outperform on August 19, 2026, adding a new positive voice to the analyst group."
   ],
   "lists": {
    "items": [
     "Analysts reaffirm positive ratings November 6, 2026·RBC Capital RBC Capital and Evercore ISI both kept Outperform ratings on November 6, 2026, the first session after the earnings report. Reaffirmations after a beat support the analyst case for further upside.",
     "Earnings beat after the November report November 5, 2026·Earnings report Adjusted EPS of $3.26 beat the $2.94 estimate by 10.88%, and the shares rose 1.46% in the next session. This is the strongest recent evidence that earnings are running ahead of expectations.",
     "Morgan Stanley keeps Overweight October 30, 2026·Morgan Stanley Morgan Stanley kept its Overweight rating on October 30, 2026, adding to a set of institutional endorsements in the weeks before the report.",
     "Mizuho maintains Outperform October 20, 2026·Mizuho Mizuho kept its Outperform rating on October 20, 2026, a reaffirmation that keeps the Street's positive stance in place ahead of the report.",
     "RBC initiates at Outperform in August August 19, 2026·RBC Capital RBC Capital started coverage at Outperform on August 19, 2026, adding a new positive voice to the analyst group."
    ]
   }
  },
  {
   "id": "ch-street",
   "title": "CAH price target 2026",
   "text": [
    "The base case is that Cardinal Health holds its gains while earnings estimates keep rising. Analysts expect EPS of $13.00 for this fiscal year, up 18.8%, and $14.29 for next fiscal year, up 9.9%. Those forecasts support the current valuation only if revenue growth picks up from the 5.50% reported in the latest quarter, which trails the sector median of 8.1%. The analysts' median 12-month target is $290.00, with a range of $260.00 to $330.00. The case would weaken if the price falls back through the 20-day EMA and 50-day SMA, or if the next quarterly report misses estimates after a run of seven straight beats. Because the stock is already overbought on RSI, a pullback is more likely to come from profit-taking than from a change in the fundamental picture."
   ],
   "tables": [
    {
     "caption": "Recent analyst rating actions on CAH",
     "columns": [
      "Date",
      "Firm",
      "Action",
      "Rating"
     ],
     "rows": [
      {
       "label": "Nov 6, 2026",
       "cells": [
        "RBC Capital",
        "Maintains",
        "Outperform"
       ]
      },
      {
       "label": "Nov 6, 2026",
       "cells": [
        "Evercore ISI Group",
        "Maintains",
        "Outperform"
       ]
      },
      {
       "label": "Oct 30, 2026",
       "cells": [
        "Morgan Stanley",
        "Maintains",
        "Overweight"
       ]
      },
      {
       "label": "Oct 20, 2026",
       "cells": [
        "Mizuho",
        "Maintains",
        "Outperform"
       ]
      },
      {
       "label": "Oct 16, 2026",
       "cells": [
        "UBS",
        "Maintains",
        "Buy"
       ]
      },
      {
       "label": "Aug 19, 2026",
       "cells": [
        "RBC Capital",
        "Initiates",
        "Outperform"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "ch-levels",
   "title": "CAH support and resistance levels",
   "text": [
    "Support sits at $256.78, the 20-day exponential moving average, which is the nearest level below the price. Below it, the 50-day simple moving average at $242.12 is the next floor, followed by the 200-day simple moving average at $224.10. The 52-week low at $180.45 is the deepest reference point. On the upside, the 52-week high at $286.29 is the first resistance; a close above it would mark a new 52-week high for the stock."
   ],
   "tables": [
    {
     "caption": "CAH support and resistance levels",
     "columns": [
      "Level",
      "What it is",
      "Price",
      "From the price"
     ],
     "rows": [
      {
       "label": "Resistance 1",
       "cells": [
        "52-week high",
        "$286.29",
        "+3.4%"
       ]
      },
      {
       "label": "Price",
       "cells": [
        "November 10, 2026",
        "$276.79",
        ""
       ]
      },
      {
       "label": "Support 1",
       "cells": [
        "20-day exponential average",
        "$256.78",
        "-7.2%"
       ]
      },
      {
       "label": "Support 2",
       "cells": [
        "50-day moving average",
        "$242.12",
        "-12.5%"
       ]
      },
      {
       "label": "Support 3",
       "cells": [
        "200-day moving average",
        "$224.10",
        "-19.0%"
       ]
      },
      {
       "label": "Support 4",
       "cells": [
        "52-week low",
        "$180.45",
        "-34.8%"
       ]
      }
     ]
    }
   ],
   "lists": {
    "items": [
     "RSI Overbought",
     "SMA cross Bullish",
     "Price vs SMA Bullish",
     "MACD Bullish"
    ]
   }
  },
  {
   "id": "ch-price",
   "title": "CAH stock price and trading"
  },
  {
   "id": "ch-fundamentals",
   "title": "CAH fundamentals and valuation",
   "text": [
    "Price to earnings vs sector: Valuation is broadly in line with sector peers (11% against the sector median P/E).",
    "Return vs XLV: Since May 29, 2025, CAH has gained 78.1% against a gain of 42.3% for XLV.",
    "Revenue growth: Revenue grew 14.2% in FY2026 to $254B, from $223B a year earlier.",
    "Profit margin: The net margin was 0.7% in FY2026, unchanged from the year before.",
    "Profitable: CAH earned $1.7B in FY2026.",
    "Earnings record: CAH beat the analyst estimate in 7 of the 7 reports in our data.",
    "Market reaction: The stock fell in the first session after 3 of those 7 beats, so a beat has not been enough on its own."
   ],
   "tables": [
    {
     "caption": "CAH earnings surprises and the stock's reaction",
     "columns": [
      "Report",
      "Estimate",
      "Actual",
      "Surprise",
      "First sessionDay 1",
      "5 sessionsDay 5"
     ],
     "rows": [
      {
       "label": "Nov 5, 2026",
       "cells": [
        "$2.94",
        "$3.26",
        "+10.88%",
        "+1.46%",
        "-"
       ]
      },
      {
       "label": "Aug 11, 2026",
       "cells": [
        "$2.42",
        "$2.60",
        "+7.44%",
        "-2.54%",
        "-2.20%"
       ]
      },
      {
       "label": "Apr 30, 2026",
       "cells": [
        "$2.79",
        "$3.17",
        "+13.62%",
        "+1.22%",
        "-3.94%"
       ]
      },
      {
       "label": "Feb 5, 2026",
       "cells": [
        "$2.37",
        "$2.63",
        "+10.97%",
        "-0.38%",
        "-5.33%"
       ]
      },
      {
       "label": "Aug 12, 2025",
       "cells": [
        "$2.03",
        "$2.08",
        "+2.46%",
        "+1.24%",
        "+1.86%"
       ]
      },
      {
       "label": "May 1, 2025",
       "cells": [
        "$2.15",
        "$2.35",
        "+9.30%",
        "+2.75%",
        "+1.20%"
       ]
      },
      {
       "label": "Jan 30, 2025",
       "cells": [
        "$1.76",
        "$1.93",
        "+9.66%",
        "-3.59%",
        "-0.94%"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "ch-history",
   "title": "CAH price history and drawdowns",
   "text": [
    "Against the market: CAH beat the S&P 500 over this period: $50,816 against $40,115.",
    "A $10,000 investment in CAH in December 2016 would be worth about $50,816 today with dividends reinvested, compared with about $40,115 for the same investment in the S&P 500 benchmark (also with dividends reinvested)."
   ]
  },
  {
   "id": "ch-scenarios",
   "title": "CAH stock price prediction 2030",
   "text": [
    "CleaRank's simulation projects a price near $392 for CAH by 2030 in the base case, from $277 today (1.4x over 4 years). The 10th-percentile path ends near $184. These are outcomes of a Monte Carlo simulation run on CAH's historical return distribution, not price targets, and they assume no dividends are reinvested."
   ],
   "tables": [
    {
     "caption": "CAH simulated price paths by year",
     "columns": [
      "Year",
      "10th percentile",
      "Base case",
      "90th percentile",
      "range base today"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$207",
        "$302",
        "$440",
        ""
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$193",
        "$329",
        "$561",
        ""
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$187",
        "$359",
        "$690",
        ""
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$184",
        "$392",
        "$832",
        ""
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "ch-insiders",
   "title": "CAH insider trading",
   "text": [
    "Net insider selling: No insider bought CAH shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would."
   ],
   "tables": [
    {
     "caption": "Insider transactions in CAH",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Aug 19, 2026",
       "cells": [
        "Jason M Hollar Chief Executive Officer",
        "Sell",
        "124.5K",
        "$29.4M"
       ]
      },
      {
       "label": "Aug 19, 2026",
       "cells": [
        "Mary C Scherer Officer",
        "Sell",
        "2.3K",
        "$546.5K"
       ]
      },
      {
       "label": "Aug 18, 2026",
       "cells": [
        "Aaron E. Alt Chief Financial Officer",
        "Sell",
        "42.0K",
        "$9.9M"
       ]
      },
      {
       "label": "Aug 18, 2026",
       "cells": [
        "Stephen M Mason Officer",
        "Sell",
        "35.0K",
        "$8.3M"
       ]
      },
      {
       "label": "Aug 18, 2026",
       "cells": [
        "Jessica L. Mayer Officer",
        "Sell",
        "29.4K",
        "$7.0M"
       ]
      },
      {
       "label": "Aug 18, 2026",
       "cells": [
        "Michelle D Greene Chief Technology Officer",
        "Sell",
        "11.7K",
        "$2.7M"
       ]
      },
      {
       "label": "Aug 18, 2026",
       "cells": [
        "Deborah Weitzman Officer",
        "Sell",
        "7.4K",
        "$1.7M"
       ]
      },
      {
       "label": "Aug 14, 2026",
       "cells": [
        "Aaron E. Alt Chief Financial Officer",
        "Grant",
        "8.1K",
        "-"
       ]
      },
      {
       "label": "Aug 14, 2026",
       "cells": [
        "Michelle D Greene Chief Technology Officer",
        "Grant",
        "2.6K",
        "-"
       ]
      },
      {
       "label": "Aug 14, 2026",
       "cells": [
        "Jason M Hollar Chief Executive Officer",
        "Grant",
        "30.6K",
        "-"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "ch-faq",
   "title": "CAH stock forecast: questions people ask",
   "text": [
    "How these figures are computed, and where the data comes from: CleaRank methodology."
   ]
  },
  {
   "id": "ch-related",
   "title": "Compare CAH with similar assets",
   "links": [
    {
     "text": "MOH Molina Healthcare Inc. NYSE $206.35 +1.48%",
     "url": "https://clearank.com/stock/moh-stock-analysis/"
    },
    {
     "text": "TEM Tempus AI Inc NASDAQ $80.55 -4.61%",
     "url": "https://clearank.com/stock/tempus-ai-tem/"
    },
    {
     "text": "EW Edwards Lifesciences Corporation NYSE $104.01 -0.67%",
     "url": "https://clearank.com/stock/ew-stock-analysis/"
    },
    {
     "text": "DHR Danaher Corp. NYSE $236.11 +0.42%",
     "url": "https://clearank.com/stock/dhr-stock-analysis/"
    },
    {
     "text": "NVAX Novavax Inc. NASDAQ $10.20 -6.34%",
     "url": "https://clearank.com/stock/novavax-nvax/"
    },
    {
     "text": "CAPR Capricor Therapeutics, Inc. NASDAQ $9.85 +9.44%",
     "url": "https://clearank.com/stock/capr-stock-analysis/"
    },
    {
     "text": "ISRG Intuitive Surgical Inc. NASDAQ $450.04 -2.28%",
     "url": "https://clearank.com/stock/intuitive-surgical-isrg/"
    },
    {
     "text": "IQV IQVIA Holdings Inc. NYSE $275.15 -1.32%",
     "url": "https://clearank.com/stock/iqvia-iqv/"
    },
    {
     "text": "XOM vs CVX Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/xom-vs-cvx/"
    },
    {
     "text": "VUG vs VOO Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vug-vs-voo/"
    },
    {
     "text": "XMR/USD vs ZEC/USD Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/xmr-vs-zec/"
    }
   ]
  }
 ],
 "faq": [
  {
   "question": "What is the CAH stock forecast?",
   "answer": "The analysts' median 12-month price target is $290.00, which is 4.8% above the price, with a range of $260.00 to $330.00 across 17 analysts. The nearest level below the price is the 20-day EMA at $256.78, and the nearest level above it is the 52-week high at $286.29. A forecast is an analyst estimate, not a guarantee of where the stock will trade."
  },
  {
   "question": "What is the CAH price target?",
   "answer": "The median 12-month analyst target is $290.00, with the lowest target at $260.00 and the highest at $330.00. The consensus rating is Buy, and the price of $276.79 sits below the median target."
  },
  {
   "question": "Is CAH a buy or sell today?",
   "answer": "Analysts rate the stock Buy on consensus, with 14 of 17 analysts rating it buy or strong buy, 3 rating it hold and none rating it sell. CleaRank's own rating is Buy, with a score of 77 out of 100, and the trend is the factor doing the most to lift it. The price of $276.79 sits 14.32% above the 50-day SMA of $242.12 and 23.51% above the 200-day SMA of $224.10."
  },
  {
   "question": "Why did CAH shares rise after the November 5, 2026 report?",
   "answer": "The shares rose 1.46% in the first trading session after the report. Adjusted EPS of $3.26 beat the $2.94 estimate by 10.88%."
  },
  {
   "question": "How has CAH performed over the past year?",
   "answer": "The stock is up 34.74% over one year and 51.62% over six months. It is 53.39% above its 52-week low of $180.45."
  },
  {
   "question": "How expensive is CAH compared with its sector?",
   "answer": "The trailing P/E of 35.49 is 11.3% above the sector median of 31.9, which places the stock broadly in line with peers. The price-to-sales ratio of 0.25 compares with a sector median of 3.4."
  },
  {
   "question": "Does CAH pay a dividend?",
   "answer": "The annual dividend per share is $2.05, which gives a trailing dividend yield of 0.74%."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "MOH",
    "name": "Molina Healthcare Inc. NYSE",
    "price": "$206.35",
    "change": "+1.48%",
    "url": "https://clearank.com/stock/moh-stock-analysis/"
   },
   {
    "ticker": "TEM",
    "name": "Tempus AI Inc NASDAQ",
    "price": "$80.55",
    "change": "-4.61%",
    "url": "https://clearank.com/stock/tempus-ai-tem/"
   },
   {
    "ticker": "EW",
    "name": "Edwards Lifesciences Corporation NYSE",
    "price": "$104.01",
    "change": "-0.67%",
    "url": "https://clearank.com/stock/ew-stock-analysis/"
   },
   {
    "ticker": "DHR",
    "name": "Danaher Corp. NYSE",
    "price": "$236.11",
    "change": "+0.42%",
    "url": "https://clearank.com/stock/dhr-stock-analysis/"
   },
   {
    "ticker": "NVAX",
    "name": "Novavax Inc. NASDAQ",
    "price": "$10.20",
    "change": "-6.34%",
    "url": "https://clearank.com/stock/novavax-nvax/"
   },
   {
    "ticker": "CAPR",
    "name": "Capricor Therapeutics, Inc. NASDAQ",
    "price": "$9.85",
    "change": "+9.44%",
    "url": "https://clearank.com/stock/capr-stock-analysis/"
   },
   {
    "ticker": "ISRG",
    "name": "Intuitive Surgical Inc. NASDAQ",
    "price": "$450.04",
    "change": "-2.28%",
    "url": "https://clearank.com/stock/intuitive-surgical-isrg/"
   },
   {
    "ticker": "IQV",
    "name": "IQVIA Holdings Inc. NYSE",
    "price": "$275.15",
    "change": "-1.32%",
    "url": "https://clearank.com/stock/iqvia-iqv/"
   }
  ],
  "comparisons": [
   {
    "ticker": "XOM vs CVX Comparison",
    "name": "",
    "url": "https://clearank.com/compare/xom-vs-cvx/"
   },
   {
    "ticker": "VUG vs VOO Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vug-vs-voo/"
   },
   {
    "ticker": "XMR/USD vs ZEC/USD Comparison",
    "name": "",
    "url": "https://clearank.com/compare/xmr-vs-zec/"
   }
  ],
  "Newly Tracked": [
   {
    "ticker": "TEVA",
    "text": "Teva Pharmaceutical Industries Ltd.",
    "url": "https://clearank.com/stock/teva-pharmaceutical-teva/"
   },
   {
    "ticker": "BAX",
    "text": "Baxter International Inc.",
    "url": "https://clearank.com/stock/baxter-bax/"
   },
   {
    "ticker": "NVAX",
    "text": "Novavax Inc.",
    "url": "https://clearank.com/stock/novavax-nvax/"
   },
   {
    "ticker": "CTVA",
    "text": "Corteva Inc.",
    "url": "https://clearank.com/stock/corteva-ctva/"
   },
   {
    "ticker": "OWL",
    "text": "Blue Owl Capital Inc.",
    "url": "https://clearank.com/stock/blue-owl-capital-owl/"
   }
  ],
  "Top Movers (latest session)": [
   {
    "ticker": "MRDN",
    "text": "↓ 23.90%",
    "url": "https://clearank.com/stock/mrdn-stock-analysis/"
   },
   {
    "ticker": "HIMS",
    "text": "↓ 16.61%",
    "url": "https://clearank.com/stock/hims-hers-health-hims/"
   },
   {
    "ticker": "LEGN",
    "text": "↓ 15.97%",
    "url": "https://clearank.com/stock/legend-biotech-legn/"
   },
   {
    "ticker": "CRSP",
    "text": "↓ 9.77%",
    "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
   },
   {
    "ticker": "QNT/USD",
    "text": "↓ 9.71%",
    "url": "https://clearank.com/crypto/qnt-usd-crypto-analysis/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "BNTX",
    "text": "BioNTech SE",
    "url": "https://clearank.com/stock/bntx-stock-analysis/"
   },
   {
    "ticker": "BSX",
    "text": "Boston Scientific Corporation",
    "url": "https://clearank.com/stock/boston-scientific-bsx/"
   },
   {
    "ticker": "CAPR",
    "text": "Capricor Therapeutics, Inc.",
    "url": "https://clearank.com/stock/capr-stock-analysis/"
   },
   {
    "ticker": "CI",
    "text": "The Cigna Group",
    "url": "https://clearank.com/stock/cigna-group-ci/"
   },
   {
    "ticker": "MCK",
    "text": "McKesson Corporation",
    "url": "https://clearank.com/stock/mck-stock-analysis/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": [
      "CleaRank Financial AI",
      "CleaRank (Clear Rank)"
     ],
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free, and so is the Free plan of its trading workbench; CleaRank is paid for by yearly Pro and Unlimited subscriptions to that workbench, which combines a trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. It uses no affiliate links and takes no payment from the brokers, prop firms or companies it rates or writes about.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@type": "Place",
      "@id": "https://clearank.com/#place",
      "address": {
       "@type": "PostalAddress",
       "streetAddress": "Beni Berman 2",
       "addressLocality": "Netanya",
       "addressRegion": "Center",
       "postalCode": "4249330",
       "addressCountry": "IL"
      }
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@type": "SoftwareApplication",
      "@id": "https://clearank.com/#app",
      "name": "CleaRank",
      "url": "https://clearank.com/"
     },
     "founder": {
      "@type": "Person",
      "@id": "https://clearank.com/writer/shaundavidb/#person",
      "name": "Shaun David",
      "url": "https://clearank.com/writer/shaundavidb/"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/og/mi/stock/cardinal-health-cah.png",
     "url": "https://clearank.com/og/mi/stock/cardinal-health-cah.png",
     "width": "1200",
     "height": "630",
     "caption": "Cardinal Health, Inc. (CAH) analysis by CleaRank",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/cardinal-health-cah/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": 1,
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": 2,
       "item": {
        "@id": "https://clearank.com/stock/",
        "name": "Stocks"
       }
      },
      {
       "@type": "ListItem",
       "position": 3,
       "item": {
        "@id": "https://clearank.com/stock/cardinal-health-cah/",
        "name": "Cardinal Health, Inc. (CAH)"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/cardinal-health-cah/#webpage",
     "url": "https://clearank.com/stock/cardinal-health-cah/",
     "name": "Cardinal Health (CAH) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-11-09T18:46:30+00:00",
     "dateModified": "2026-11-09T18:46:30+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/og/mi/stock/cardinal-health-cah.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/cardinal-health-cah/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/jacob-bakshi/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/jacob-bakshi/#person",
     "name": "Jacob Bakshi",
     "jobTitle": "Senior Market Strategist",
     "url": "https://clearank.com/writer/jacob-bakshi/",
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/cardinal-health-cah/#richSnippet",
     "headline": "Cardinal Health (CAH) Stock Forecast & Price Target (2026)",
     "name": "Cardinal Health (CAH) Stock Forecast & Price Target (2026)",
     "description": "Cardinal Health (CAH) stock forecast 2026: buy, hold or sell? Analysts see a median target of $290. Topped estimates in 7 of 7 reports.",
     "datePublished": "2026-11-09T18:46:30+00:00",
     "dateModified": "2026-11-09T18:46:30+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/market-insights/methodology/",
     "about": {
      "@type": "Corporation",
      "name": "Cardinal Health, Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "CAH"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "Cardinal Health, Inc. is a healthcare services and products company that supports the flow of medicines, medical supplies, and related solutions across the healthcare system.",
      "tickerSymbol": "CAH",
      "sameAs": "https://www.cardinalhealth.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/cardinal-health-cah/#webpage"
     },
     "image": {
      "@type": "ImageObject",
      "url": "https://clearank.com/og/mi/stock/cardinal-health-cah.png",
      "width": 1200,
      "height": 630
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/cardinal-health-cah/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is the CAH stock forecast?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The analysts' median 12-month price target is $290.00, which is 4.8% above the price, with a range of $260.00 to $330.00 across 17 analysts. The nearest level below the price is the 20-day EMA at $256.78, and the nearest level above it is the 52-week high at $286.29. A forecast is an analyst estimate, not a guarantee of where the stock will trade."
     }
    },
    {
     "@type": "Question",
     "name": "What is the CAH price target?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The median 12-month analyst target is $290.00, with the lowest target at $260.00 and the highest at $330.00. The consensus rating is Buy, and the price of $276.79 sits below the median target."
     }
    },
    {
     "@type": "Question",
     "name": "Is CAH a buy or sell today?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Analysts rate the stock Buy on consensus, with 14 of 17 analysts rating it buy or strong buy, 3 rating it hold and none rating it sell. CleaRank's own rating is Buy, with a score of 77 out of 100, and the trend is the factor doing the most to lift it. The price of $276.79 sits 14.32% above the 50-day SMA of $242.12 and 23.51% above the 200-day SMA of $224.10."
     }
    },
    {
     "@type": "Question",
     "name": "Why did CAH shares rise after the November 5, 2026 report?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The shares rose 1.46% in the first trading session after the report. Adjusted EPS of $3.26 beat the $2.94 estimate by 10.88%."
     }
    },
    {
     "@type": "Question",
     "name": "How has CAH performed over the past year?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The stock is up 34.74% over one year and 51.62% over six months. It is 53.39% above its 52-week low of $180.45."
     }
    },
    {
     "@type": "Question",
     "name": "How expensive is CAH compared with its sector?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The trailing P/E of 35.49 is 11.3% above the sector median of 31.9, which places the stock broadly in line with peers. The price-to-sales ratio of 0.25 compares with a sector median of 3.4."
     }
    },
    {
     "@type": "Question",
     "name": "Does CAH pay a dividend?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The annual dividend per share is $2.05, which gives a trailing dividend yield of 0.74%."
     }
    }
   ]
  }
 ]
}